Scholarlink

Background <p>Hemodynamic instability during colonoscopy sedation remains a significant clinical concern. Esketamine’s sympathomimetic properties may protect against these risks while reducing sedative requirements. Hence, we aim to evaluate the efficacy and safety of esketamine in improving intraprocedural sedation during colonoscopy.</p> Methods <p>We systematically searched PubMed, Scopus, CENTRAL, and Web of Science until June 2025 for randomized controlled trials. The primary outcome was the incidence of intraprocedural hypotension; secondary outcomes included bradycardia, hypoxemia, and recovery parameters. Dichotomous outcomes were pooled using risk ratios (RR) and continuous outcomes using standardized mean differences (SMD), with heterogeneity assessed via I² statistics. PROSPERO ID: CRD420251105691.</p> Results <p>Five randomized controlled trials comprising 858 patients were included in our analysis. Esketamine significantly reduced the risk of intraprocedural hypotension (RR: 0.34, 95% CI 0.22–0.53; I²=58%) and the incidence of hypoxemia (RR: 0.38, 95% CI 0.19–0.73; I²=0%). A reduction in injection pain was also observed (RR: 0.42, 95% CI 0.19–0.97; I²=80.5%), though this finding showed sensitivity in leave-one-out analysis. No significant differences were found between groups in bradycardia risk (RR: 0.51, 95% CI 0.23–1.14), total propofol requirement (SMD: -0.23, 95% CI -0.50 to 0.04), induction time, or procedure duration. The reduction in hypotension remained robust in sensitivity analyses.</p> Conclusion <p>Esketamine significantly enhanced hemodynamic stability and reduced sedative demand during colonoscopy without delaying recovery, supporting its use in high-risk patients.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Efficacy and safety of esketamine for sedation during colonoscopy: A systematic review and Meta-analysis of randomized controlled trials

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月17日

查看全文
  • Zainab Hussein,
  • Amira Mohamed Taha,
  • Alaa Abdrabou Abouelmagd,
  • Mohamed Nasser Elshabrawi,
  • Abdul Karim Durvesh,
  • Eman Ayman Nada,
  • Mohamed Abuelazm,
  • Mohamed Elnaggar,
  • Ismail Elkhattib

摘要

Background

Hemodynamic instability during colonoscopy sedation remains a significant clinical concern. Esketamine’s sympathomimetic properties may protect against these risks while reducing sedative requirements. Hence, we aim to evaluate the efficacy and safety of esketamine in improving intraprocedural sedation during colonoscopy.

Methods

We systematically searched PubMed, Scopus, CENTRAL, and Web of Science until June 2025 for randomized controlled trials. The primary outcome was the incidence of intraprocedural hypotension; secondary outcomes included bradycardia, hypoxemia, and recovery parameters. Dichotomous outcomes were pooled using risk ratios (RR) and continuous outcomes using standardized mean differences (SMD), with heterogeneity assessed via I² statistics. PROSPERO ID: CRD420251105691.

Results

Five randomized controlled trials comprising 858 patients were included in our analysis. Esketamine significantly reduced the risk of intraprocedural hypotension (RR: 0.34, 95% CI 0.22–0.53; I²=58%) and the incidence of hypoxemia (RR: 0.38, 95% CI 0.19–0.73; I²=0%). A reduction in injection pain was also observed (RR: 0.42, 95% CI 0.19–0.97; I²=80.5%), though this finding showed sensitivity in leave-one-out analysis. No significant differences were found between groups in bradycardia risk (RR: 0.51, 95% CI 0.23–1.14), total propofol requirement (SMD: -0.23, 95% CI -0.50 to 0.04), induction time, or procedure duration. The reduction in hypotension remained robust in sensitivity analyses.

Conclusion

Esketamine significantly enhanced hemodynamic stability and reduced sedative demand during colonoscopy without delaying recovery, supporting its use in high-risk patients.